Aravive, Inc. 4 SEC Filings

Filed On	Filing
11 Apr 2023	Form 4: Petrini Maria Carolina, Chief Commercial Officer Granted 400,000 Nonqualified Stock Option (Right to Buy)
02 Feb 2023	Form 4: McIntyre Gail Frances, Director Granted 700,000 Stock Option (Right to Buy)
02 Feb 2023	Form 4: Geller Robert B., Chief Medical Officer Granted 400,000 Stock Option (Right to Buy)
02 Feb 2023	Form 4: Howard Rudy, Chief Financial Officer Granted 400,000 Stock Option (Right to Buy)
02 Feb 2023	Form 4: Dove Leonard Scott, Chief Operating Officer Granted 400,000 Stock Option (Right to Buy)
26 Oct 2022	Form 4: Giaccia Amato, Director Received 271,768 shares as a grant or award ($250K) · Granted 135,884 Series A Warrants (right to buy) · Granted 135,884 Series B Warrants (right to buy)
26 Oct 2022	Form 4: Zhang Eric, Director Received 543,537 shares as a grant or award ($500K) · Granted 271,769 Series A Warrants (right to buy) · Granted 271,768 Series B Warrants (right to buy)
26 Oct 2022	Form 4: Howard Rudy, Chief Financial Officer Received 10,870 shares as a grant or award ($10K) · Granted 5,435 Series A Warrants (right to buy) · Granted 5,435 Series B Warrants (right to buy)
26 Oct 2022	Form 4: McIntyre Gail Frances, Director Received 54,353 shares as a grant or award ($50K) · Granted 27,177 Series A Warrants (right to buy) · Granted 27,176 Series B Warrants (right to buy)
26 Oct 2022	Form 4: Ho Peter Tai-Ching, Director Received 54,353 shares as a grant or award ($50K) · Granted 27,177 Series A Warrants (right to buy) · Granted 27,176 Series B Warrants (right to buy)
26 Oct 2022	Form 4: Eshelman Fredric N, Director and 1 other Received 16,306,120 shares as a grant or award ($15M) · Granted 8,153,060 Series A Warrants (right to buy) · Granted 8,153,060 Series B Warrants (right to buy)
26 Sep 2022	Form 4: Kirk Sigurd, Director Granted 97,063 Stock Option (Right to Buy)
26 Sep 2022	Form 4: Rogers Michael W, Director Granted 97,063 Stock Option (Right to Buy)
26 Sep 2022	Form 4: Zhang Eric, Director Granted 97,063 Stock Option (Right to Buy)
26 Sep 2022	Form 4: Eshelman Fredric N, Director and 1 other Granted 97,063 Stock Option (Right to Buy)
26 Sep 2022	Form 4: Giaccia Amato, Director Granted 97,063 Stock Option (Right to Buy)
26 Sep 2022	Form 4: Ho Peter Tai-Ching, Director Granted 97,063 Stock Option (Right to Buy)
26 Sep 2022	Form 4: Hohneker John, Director Granted 97,063 Stock Option (Right to Buy)
05 Jul 2022	Form 4: Geller Robert B., Chief Medical Officer Granted 200,000 Stock Option
03 Jun 2022	Form 4: Howard Rudy, Chief Financial Officer Granted 290,000 Stock Option

Comments